Febuxostat Approved for Gout Treatment

FDA

FDA

On February 19, 2009, the US Food and Drug Administration (FDA) approved the licensing of febuxostat for the treatment of hyperuricemia in patients with chronic gout.  This is the only approved indication for the drug at this time.  Febuxostat will be marketed under the trade name Uloric and is manufactured by Takeda Pharmaceuticals.  Links to summaries of clinical trials of febuxostat previously posted on this website are accessed at the following links:

Jon Giles, MD

About Jon Giles, MD